Hims & Hers Health CEO Discloses $33M Stock Sale Amid Share Price Decline.

Hims & Hers Health CEO Andrew Dudum disclosed the sale of over $33M worth of company stock, causing shares to trade lower for the second straight session. The transaction follows a weight loss product recall and a reported SEC investigation into the company's marketing practices.

Hims & Hers Health, Inc. (NYSE: HIMS) has seen its stock price fall for the second consecutive session following a significant sale of company stock by CEO Andrew Dudum. On August 7, Dudum sold 660,000 shares at an average price of $50.58, totaling approximately $33.4 million [2]. This transaction represents a 22.96% decrease in his ownership stake, leaving him with approximately 2,214,769 shares valued at approximately $112.02 million [2].

The sale comes amid a weight loss product recall and a reported Securities and Exchange Commission (SEC) investigation into Hims & Hers' marketing practices. The company has faced allegations of deceptive promotion and selling of illegitimate, knockoff versions of Wegovy, which put patient safety at risk [1]. The SEC investigation, along with the product recall, has raised concerns among investors.

Analysts have responded to the recent developments with a cautious outlook. The stock currently has an average rating of "Hold" from analysts, with a target price averaging $39.83 [2]. The stock has experienced volatility, with a one-year low of $13.47 and a high of $72.98 [2].

Institutional investors have also shown interest in Hims & Hers Health. Hedge funds such as Quaker Wealth Management LLC, Bessemer Group Inc., and UMB Bank n.a. have recently bought or increased their stakes in the company [2]. However, the recent developments have led to a decrease in Dudum's ownership stake and a drop in the stock price.

The company's stock performance has been closely watched by investors and financial professionals. Hims & Hers Health reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01) [2]. The company's revenue was up 72.6% compared to the same quarter last year, but the earnings miss has raised concerns about the company's financial health.

In summary, the sale of $33 million worth of stock by CEO Andrew Dudum, combined with a product recall and SEC investigation, has led to a decline in Hims & Hers Health's stock price. The company faces challenges in addressing the allegations and maintaining investor confidence.

References:
[1] https://www.morningstar.com/news/business-wire/20250811128211/hims-class-action-reminder-kessler-topaz-meltzer-check-llp-reminds-hims-hers-health-inc-investors-of-securities-fraud-class-action-lawsuit-deadline
[2] https://www.marketbeat.com/instant-alerts/hims-hers-health-inc-nysehims-ceo-andrew-dudum-sells-660000-shares-2025-08-11/